224 related articles for article (PubMed ID: 31480543)
1. Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau.
Jeong H; Shin S; Lee JS; Lee SH; Baik JH; Lim S; Kim YK
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31480543
[TBL] [Abstract][Full Text] [Related]
2. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.
Carlomagno Y; Chung DC; Yue M; Castanedes-Casey M; Madden BJ; Dunmore J; Tong J; DeTure M; Dickson DW; Petrucelli L; Cook C
J Biol Chem; 2017 Sep; 292(37):15277-15286. PubMed ID: 28760828
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model.
Janczura KJ; Volmar CH; Sartor GC; Rao SJ; Ricciardi NR; Lambert G; Brothers SP; Wahlestedt C
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):E11148-E11157. PubMed ID: 30397132
[TBL] [Abstract][Full Text] [Related]
4. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance.
Cook C; Carlomagno Y; Gendron TF; Dunmore J; Scheffel K; Stetler C; Davis M; Dickson D; Jarpe M; DeTure M; Petrucelli L
Hum Mol Genet; 2014 Jan; 23(1):104-16. PubMed ID: 23962722
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
Noack M; Leyk J; Richter-Landsberg C
Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
[TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
7. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
Fan SJ; Huang FI; Liou JP; Yang CR
Cell Death Dis; 2018 May; 9(6):655. PubMed ID: 29844403
[TBL] [Abstract][Full Text] [Related]
8. Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Tan H; Wu W; Xu M; Pineda-Lucena A; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Sep; 10(9):4076-4101. PubMed ID: 31441641
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
Tseng HJ; Lin MH; Shiao YJ; Yang YC; Chu JC; Chen CY; Chen YY; Lin TE; Su CJ; Pan SL; Chen LC; Wang CY; Hsu KC; Huang WJ
Eur J Med Chem; 2020 Apr; 192():112193. PubMed ID: 32151835
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
Konsoula Z; Barile FA
J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
[TBL] [Abstract][Full Text] [Related]
11. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
12. Identification of retinoblastoma binding protein 7 (Rbbp7) as a mediator against tau acetylation and subsequent neuronal loss in Alzheimer's disease and related tauopathies.
Dave N; Vural AS; Piras IS; Winslow W; Surendra L; Winstone JK; Beach TG; Huentelman MJ; Velazquez R
Acta Neuropathol; 2021 Aug; 142(2):279-294. PubMed ID: 33978814
[TBL] [Abstract][Full Text] [Related]
13. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
[TBL] [Abstract][Full Text] [Related]
14. Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Mar; 10(3):1765-1782. PubMed ID: 30525452
[TBL] [Abstract][Full Text] [Related]
15. Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models.
Choi H; Kim HJ; Yang J; Chae S; Lee W; Chung S; Kim J; Choi H; Song H; Lee CK; Jun JH; Lee YJ; Lee K; Kim S; Sim HR; Choi YI; Ryu KH; Park JC; Lee D; Han SH; Hwang D; Kyung J; Mook-Jung I
Aging Cell; 2020 Jan; 19(1):e13081. PubMed ID: 31763743
[TBL] [Abstract][Full Text] [Related]
16. M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory.
Volmar CH; Salah-Uddin H; Janczura KJ; Halley P; Lambert G; Wodrich A; Manoah S; Patel NH; Sartor GC; Mehta N; Miles NTH; Desse S; Dorcius D; Cameron MD; Brothers SP; Wahlestedt C
Proc Natl Acad Sci U S A; 2017 Oct; 114(43):E9135-E9144. PubMed ID: 29073110
[TBL] [Abstract][Full Text] [Related]
17. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model.
Cuadrado-Tejedor M; Ricobaraza AL; Torrijo R; Franco R; Garcia-Osta A
Curr Pharm Des; 2013; 19(28):5076-84. PubMed ID: 23448463
[TBL] [Abstract][Full Text] [Related]
18. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.
Santini A; Tassinari E; Poeta E; Loi M; Ciani E; Trazzi S; Piccarducci R; Daniele S; Martini C; Pagliarani B; Tarozzi A; Bersani M; Spyrakis F; Danková D; Olsen CA; Soldati R; Tumiatti V; Montanari S; De Simone A; Milelli A
ACS Chem Neurosci; 2024 Jun; 15(11):2099-2111. PubMed ID: 38747979
[TBL] [Abstract][Full Text] [Related]
19. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
Bush EW; McKinsey TA
Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
[TBL] [Abstract][Full Text] [Related]
20. Screening of a neuronal cell model of tau pathology for therapeutic compounds.
Pickhardt M; Tassoni M; Denner P; Kurkowsky B; Kitanovic A; Möhl C; Fava E; Mandelkow E
Neurobiol Aging; 2019 Apr; 76():24-34. PubMed ID: 30640040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
